The augmentation of selective serotonin reuptake inhibitors with antipsychotics that have a high dopamine-receptor-D2 affinity may be effective in treatment-resistant obsessive-compulsive disorder and somatic symptom disorder, which is similar to illness anxiety disorder. Blonanserin, a novel antipsychotic developed in Japan, has a high affinity for the D2 receptor and weak or very little affinity for other receptors. This article presents two case studies that demonstrate the efficacy of blonanserin augmentation for treatment-resistant somatic symptom disorder. Two patients with treatment-resistant somatic symptom disorder were prescribed concomitant use of blonanserin. Augmentation with blonanserin resulted in the remarkable amelioration of all symptoms. Sedative adverse drug reactions produced by aripiprazole were improved after replacing it with blonanserin. Blonanserin is effective in treatment-resistant somatic symptom disorder. Furthermore, compared with aripiprazole, blonanserin is more likely to result in medication adherence in patients with somatic symptom disorder because it reduced adverse drug reactions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0000000000000134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells.
Biomedicines
December 2024
School of Health Sciences, IMU University, Kuala Lumpur 57000, Malaysia.
Background/objectives: (ALS), or Lou Gehrig's disease, is a debilitating, incurable neurodegenerative disorder characterised by motor neuron death in the spinal cord, brainstem, and motor cortex. With an incidence rate of about 4.42 cases per 100,000 people annually, ALS severely impacts motor function and quality of life, causing progressive muscle atrophy, spasticity, paralysis, and eventually death.
View Article and Find Full Text PDFValidation of the somatic symptom disorder-B Criteria Scale (SSD-12) in Bangladesh.
PLoS One
January 2025
Department of Clinical Psychology, University of Dhaka, Bangladesh.
Background: The absence of a reliable and valid Bangla instrument for measuring somatic symptom disorder hinders research and clinical activities in Bangladesh. The present study aimed at translating and validating the Somatic Symptom Disorder-B criteria (SSD-12).
Method: A cross-sectional design was used with purposively selected clinical (n = 100) and non-clinical (n = 100) samples.
Bridging animal models and humans: neuroimaging as intermediate phenotypes linking genetic or stress factors to anhedonia.
BMC Med
January 2025
Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, 264 Guangzhou Street, Nanjing, China.
Background: Intermediate phenotypes, such as characteristic neuroimaging patterns, offer unique insights into the genetic and stress-related underpinnings of neuropsychiatric disorders like depression. This study aimed to identify neuroimaging intermediate phenotypes associated with depression, bridging etiological factors to behavioral manifestations and connecting insights from animal models to diverse clinical populations.
Methods: We analyzed datasets from both rodents and humans.
The clinical phenomenology of skin-picking disorder - Are there any obsessive-compulsive components?
Compr Psychiatry
January 2025
Clincial Psychology, University of Graz, Austria. Electronic address:
Background: Skin-picking disorder (SPD) is currently conceptualized as a condition related to obsessive-compulsive disorder (OCD). The present study investigated whether the emotional, cognitive, and somatic components of skin-picking episodes align with this conceptual framework.
Method: A total of 134 patients diagnosed with SPD (mean age = 32 years; 84 % female; average symptom duration: 16 years) underwent in-person clinical assessment.
Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations.
Brain Behav Immun Health
February 2025
Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, Italy.
Interest in preventative dietary interventions for human health has increasingly focused on the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective properties. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at collecting and comprehensively discussing all available data from Randomized Controlled Trials (RCTs) evaluating the efficacy and tolerability of PEA supplementation across human illnesses in patient populations. Overall, 48 eligible outputs from 47 RCTs were extracted, covering neuropsychiatric ( = 15), neurological ( = 17), somatic ( = 13), and visceral ( = 11) disturbances, as well as PEA effects on blood/plasma or other tissue biomarkers ( = 10).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!